ARTICLE | Finance
Plus: Roche’s Alecensa meets in ALK-positive NSCLC and updates from Carisma and FindCure
By BioCentury Staff
September 1, 2023 11:16 PM UTC
China and Boston-based mRNA vaccine company Innovac Therapeutics raised $18 million in a series pre-A round. Investors included Elikon Venture, Vision Plus Capital, Yunion Healthcare Ventures and TG Sino-Dragon Fund. Innovac co-founders include CEO Michael Zhang, President and CSO Nicholas Valiante and CTO Hang Yuan. The biotech’s lead preclinical program, INV001, is an mRNA vaccine for an undisclosed infectious disease.
Roche (SIX:ROG; OTCQX:RHHBY) reported that Alecensa alectinib met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis in the Phase III ALINA trial, making it the first ALK inhibitor to show benefit in the adjuvant setting for ALK-positive non-small cell lung cancer (NSCLC). The study enrolled 257 patients with completely resected stage IB-IIIA ALK-positive NSCLC who were then given adjuvant therapy with either Alecensa or platinum-based chemotherapy. Overall survival data were immature at the time of the analysis, and Roche said detailed results from the study will be presented at a future medical meeting. Roche reported Alecensa sales of CHF758 million ($843.1 million) in 1H23…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://www.biocentury.com/article/649115/sept-1-quick-takes-mrna-play-innovac-raises-18m-series-pre-a-round
